ONCOhabitats for surgical and treatment planning in IDH‑wildtype glioblastoma
Official title: Feasibility Evaluation of ONCOhabitats for Supporting Surgical and Therapeutic Planning in Patients With IDH-Wildtype Glioblastoma (SINUE)
Run by Universitat Politècnica de València · NCT07111195 · Data updated 2026-11-12
This project will try ONCOhabitats MRI software to see if its tumor 'habitat' maps can predict outcomes and help adults with IDH‑wildtype glioblastoma who are having surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Universitat Politècnica de València Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 5 sites (Alicante and 4 other locations) |
| Status | Recruiting |
| Started | July 16, 2024 |
| Main results expected | September 2026 |
| Study ends | September 2026 |
| Registry record updated | August 8, 2025 |
| Trial ID | NCT07111195 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with radiologic high‑grade glioma consistent with IDH‑wildtype who are candidates for surgical resection, can undergo the required preoperative MRI (including DSC perfusion), and can give informed consent.
✕Probably not a fit
Patients who are deemed inoperable, lack the required MRI sequences or quality for processing, or withdraw consent are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will use ONCOhabitats software to analyze preoperative MRI scans and segment IDH‑wildtype glioblastomas into four biological habitats (HAT, LAT, IPE, VPE). The study will collect tissue samples from those habitats when surgically feasible and link imaging biomarkers, including perfusion-derived measures, to overall survival and treatment responses such as temozolomide and immunotherapy. It is an observational study enrolling adults scheduled for tumor resection who have the required MRI sequences, including DSC perfusion. The goal is prospective clinical validation of ONCOhabitats as a decision-support tool for prognosis and treatment planning.
Why it matters
Potential benefit: If successful, ONCOhabitats could provide noninvasive maps that help personalize surgical and medical treatment and better predict survival for patients with IDH‑wildtype glioblastoma.
How similar studies have gone: Preliminary research using MRI habitat mapping and perfusion biomarkers has shown promising correlations with tumor biology and prognosis, but prospective clinical validation in IDH‑wildtype glioblastoma remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years old) at the time of diagnosis * Radiological diagnosis of high-grade glioma * Candidates for surgical resection * Availability of complete preoperative MRI studies, including: * T1-weighted MRI (pre- and post-gadolinium) * T2-weighted MRI * FLAIR (Fluid-Attenuated Inversion Recovery) * T2\*-weighted DSC perfusion MRI * Signed informed consent to participate in the clinical study Exclusion Criteria: * Patients who do not provide informed consent * Patients deemed inoperable Withdrawal criteria: * MRI data that cannot be processed using ONCOhabitats * Patient withdraws informed consent at any time
Where it's running
-
Hospital General Universitario Dr. Balmis
Alicante, Spain Recruiting -
Hopsital Universitari Vall d'Hebron
Barcelona, Spain Recruiting -
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain Recruiting -
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Spain Recruiting -
Hospital Clínic i Universitari de València
Valencia, Spain Recruiting
Study contacts
- Study coordinator: Juan Miguel García Gómez, PhD, Full Professor
- Email: juanmig@upv.es
- Phone: +34 963877069
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TTFields with FET-PET–Guided SRS for Recurrent Glioblastoma
This trial tests whether adding FET-PET-guided stereotactic radiosurgery to TTFields helps adults with recurrent IDH-wildtype glioblastoma live longer than TTFields alone.
-
LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma
This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.
-
Metabolic, transcriptomic, and proteomic profiling of relapsed glioblastoma
This project will see if comparing genes, proteins, and metabolism in original versus relapsed tumors can reveal markers or targets for people with relapsed IDH‑wildtype glioblastoma who had repeat surgery at CHU de Bordeaux.
-
Combining eflornithine and temozolomide for newly diagnosed glioblastoma
This study is testing a new combination of two medications, eflornithine and temozolomide, to find the best dose for people with newly diagnosed glioblastoma.
-
Combining Debio 0123 with Temozolomide for Glioblastoma Treatment
This study is testing if a new drug called Debio 0123, when combined with the standard treatment temozolomide, can help adults with glioblastoma feel better and improve their outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.